heart disease

[키워드] Abu addition age antibody Antibody Response Antibody responses Asymptomatic average average age camostat characteristics of patient Cohort combinations Community Comorbidities concerning Contact contributed cough country COVID 19 COVID-19 COVID-19 infection COVID19 Critical care defined demographics develop diabete diabetes dialysis disease drug End stage kidney disease examined family Favipiravir Haemodialysis heart disease Hydroxychloroquine hypertension ICU IgG antibody individual infected individual infected individuals Infection Ischaemic heart disease Isolation Kidney disease lack Local Lopinavir lower mortality majority male median time Mild Mild disease Mortality Most patients negative PCR test outcome overall mortality Patient patients PCR PCR positive patient PCR positivity PCR tests performed Population positive patient positive patients presenting symptoms Rapid required Result Ritonavir Screening screening strategy serology source of infection spread of COVID-19 steroid Steroids study period subset symptomatic tested the antibody response Tocilizumab Viral viral clearance was performed were used with COVID-19
[DOI] 10.1186/s12882-021-02378-y PMC 바로가기 [Article Type] Research